Medida de fomento de la confianza "G"

Instalaciones de producción de vacunas

Influenza: Manufacture of influenza vaccine based on WHO recommendations

Anthrax vaccine manufacture

The BioReliance® Services business of Merck KGaA is primarily a Contract Testing Organisation, providing biosafety testing services for a wide range of global, biopharmaceutical companies.

The Glasgow facility also has a biomanufacturing facility. No products are manufactured for direct sale - only contract manufacturing for others. Typical products produced are (i) Cell Banks, (ii) Virus Seed Stocks and (iii) Viral Vectors.

Japanese Encephalitis Viral Vaccine

Valneva manufactures Japanese Encephalitis Viral vaccine (IXIARO®/JESPECT®) at its cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

During 2020 Influenza vaccines and the adjuvant MF59 were manufactured at this facility: three distinct products for the market, Agrippal®, Fluad® and Fluad QIV®, (seasonal influenza strain presentations, the latter two formulated with MF59 adjuvant).

Northern Hemisphere Influenza vaccine: Cultivation of egg adapted influenza viruses. Four strains are incorporated within the vaccine (Quadrivalent), trade name Fluad QIV®. Three strains are incorporated within the vaccine (Trivalent), trade name Agrippal® or Fluad®.

Covid-19 Vaccine manufacture

Cobra Biologics, Keele is an MHRA licensed facility for the contract development and manufacture of Investigational Medicinal products; these being cell banks (microbial and mammalian), plasmid DNA and viral vector products for gene therapy uses.  Currently we are producing the COVID-19 vaccine AZD1222 bulk drug substance.